A faster lane towards effective therapies of childhood brain cancer

On November 6, 2018, Posted by , In News, By ,, , With Comments Off on A faster lane towards effective therapies of childhood brain cancer

Scientists of the „Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ), the German Cancer Consortium (DKTK) and the German Cancer Research Center (DKFZ), in collaboration with colleagues from Seattle, U.S.A., have built a collection of tumor models that can be used to test anticancer drugs for treating childhood brain…

DKFZ/HI-STEM – Breast cancer: Stress signaling promotes metastasis and therapy resistance

On November 6, 2018, Posted by , In News, By , , With Comments Off on DKFZ/HI-STEM – Breast cancer: Stress signaling promotes metastasis and therapy resistance

Scientists from the German Cancer Research Centre (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH) have identified a central switch protein in breast cancer that promotes tumor metastasis in response to cellular stress. The switch triggers a stem cell program in the cancer cells…

Immune oncology and beyond at the first joint BioRN and Ci3 Annual Conference

On October 26, 2018, Posted by , In Press Releases, By , , With Comments Off on Immune oncology and beyond at the first joint BioRN and Ci3 Annual Conference

Darmstadt, October 26, 2018 The BioRN Life Science Cluster Rhine-Neckar in Heidelberg and the Cluster for Individualized ImmuneIntervention (Ci3) in Mainz were the organizers of yesterday’s Joint BioRN & Ci3 Annual Conference titled “Immunotherapy and beyond – The next generation of cancer treatment“. 200 participants – members and partners of…

DKFZ: Takeda Oncology Research Award 2018 to Rocio Sotillo

On October 19, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ: Takeda Oncology Research Award 2018 to Rocio Sotillo

A certain form of lung cancer is characterized by two genes that are accidentally fused. The fusion produces a growth signal for the cells. These tumors respond well to a targeted drug that deprives the cancer cells of the growth stimulus. Several molecular variants of cancer-promoting gene fusion exist. Rocio…

Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research

On October 15, 2018, Posted by , In News, By , , With Comments Off on Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research

Ready-to-use kits determine genomic characteristics of solid tumours Optimized workflow to generate results in house Software analysis allows correlation to AVENIO ctDNA NGS kits Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global commercial launch of three new next-generation sequencing (NGS) AVENIO Tumor Tissue Analysis Kits – the AVENIO…

Breast cancer: Towards individualized therapy

On October 8, 2018, Posted by , In News, By , , With Comments Off on Breast cancer: Towards individualized therapy

Breast cancer is as manifold as are those who are affected. Therefore, scientists and physicians from the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and the National Center for Tumor Diseases (NCT) in Heidelberg are generating genetic profiles from metastatic tissue samples before they choose, on this basis,…

Preclinical Efficacy Data of Apogenix’ HERA – CD27L Published in Frontiers in Oncology

On October 4, 2018, Posted by , In News, By , With Comments Off on Preclinical Efficacy Data of Apogenix’ HERA – CD27L Published in Frontiers in Oncology

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that new data published in the current volume of Frontiers in Oncology demonstrate the potent anti – tumor efficacy of Apogenix’ HERA – CD27L. In contrast to antibodies in development, HERA – CD27L is the first true CD27 receptor…

Cutting-edge research and social-economic issues of precision oncology at the first Visionary Seminar in Heidelberg

On September 27, 2018, Posted by , In Press Releases, By , , With Comments Off on Cutting-edge research and social-economic issues of precision oncology at the first Visionary Seminar in Heidelberg

Heidelberg, 27.09.2018 On Tuesday September 25, the first Visionary Seminar in Heidelberg focusing on “Precision Oncology”  attracted around 100 participants to learn and discuss about most recent research advancements and cutting-edge technologies in the field, with a focus on their social-economic impact.   Closing panel discussion: Prof. De Nys (Chair…

DKFZ: A healthy lifestyle reduces the risk of colon cancer – regardless of the genetic risk profile

On September 18, 2018, Posted by , In News, By , , With Comments Off on DKFZ: A healthy lifestyle reduces the risk of colon cancer – regardless of the genetic risk profile

The risk of developing bowel cancer depends, among other things, on lifestyle. Scientists from the German Cancer Research Center were able to show that everyone can reduce their personal risk of colon cancer by combining as many of five healthy lifestyles as possible: non-smoking, low alcohol consumption, a healthy diet,…

DKFZ: Figures for Germany determined for the first time: Avoidable risk factors cause 37 percent of all cancer cases

On September 10, 2018, Posted by , In News, By , , With Comments Off on DKFZ: Figures for Germany determined for the first time: Avoidable risk factors cause 37 percent of all cancer cases

How many cancer cases in Germany are attributable to risk factors that we can influence ourselves? How many cancer cases are linked to cigarette smoking, being overweight or physical inactivity and, thus, are potentially preventable? Scientists from the German Cancer Research Center (DKFZ) have now calculated these figures for Germany…